This will significantly expand trial capacity for Duchenne Muscular Dystrophy in the UK, particularly in the north west of England.

The charity's co-founder Alex Johnson -- recently awarded the Pride of Manchester -- said it was a huge boost to research in the region.

We are pleased to announce that Catabasis Pharmaceutical's PolarisDMD Phase 3 trial for edasalonexent is now recruiting in the UK at Bristol Royal Hospital for Children. Evelina London Children's Hospital, Great Ormond Street Hospital and Royal Manchester Children’s Hospital will begin recruitment soon.

We are pleased to announce that the VISION-DMD Phase 2b clinical trial has begun recruitment at Newcastle upon Tyne NHS Hospital Foundation Trust and Royal Hospital for Children, Glasgow.

This article was originally published on Muscular Dystrophy News.

Bristol Royal Hospital for Children joins the DMD Hub as a Hub site.

Duchenne UK is pleased to share a report from Great Ormond Street about the positive impact of the clinical staff posts we fund at the hospital.

Duchenne UK announces £46,930 in funding at Birmingham Heartlands Hospital. This funding will provide dedicated consultant time to DMD trials and provide physiotherapy equipment.

Last Thursday, our co-founder Alex Johnson attended the opening of the Clinical Research Facility at Leeds Children's Hospital which has recently joined the DMD Hub.